Leidos Holdings, Inc. Declares Quarterly Cash Dividend
April 29, 2024 at 03:48 pm
Share
RESTON, Va. - Leidos Holdings, Inc. (NYSE:LDOS) today announced that its Board of Directors has declared a quarterly cash dividend of $0.38 per outstanding share of common stock of Leidos Holdings, Inc. The cash dividend is payable on June 28, 2024, to stockholders of record as of the close of business on June 14, 2024.
About Leidos
Leidos is a Fortune 500 innovation company rapidly addressing the world's most vexing challenges in national security and health. The company's global workforce of 47,000 collaborates to create smarter technology solutions for customers in heavily regulated industries. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023. For more information, visit www.leidos.com.
Leidos Holdings, Inc. specializes in the provision of engineering, technological and scientific services. Net sales by business segment break down as follows:
- defense (56.6%): design, engineering and integration of technological solutions for intelligence, airborne surveillance and reconnaissance, maritime and land-based solutions, electronic warfare systems, and automated sensor, alarm, command and control systems, software development, cyber security solutions and data processing and analysis solutions, IT infrastructure development and integration, etc.;
- civil security (23.7%): development and integration of solutions for the protection of goods, data and digital information, solutions and systems for air traffic flow control and flight data management, vehicle and cargo inspection, explosives and radiation detection, computer security, environmental management, nuclear security, complex logistics management, etc.;
- health (19.7%): integration of complex systems and technological infrastructures for the management of data, medical information and electronic health records, provision of healthcare services, IT systems lifecycle management, research and development of biopharmaceuticals, etc.
Net sales by market are divided between the US Department of Defense and the intelligence community (49.4%), government agencies (37.4%) and commercial customers (13.2%).
The United States accounts for 91,4% of net sales.